Results about: drug design

A study reveals the effectiveness of a cognitive enhancer for schizophrenia treatment

Compound IPR19, a drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.

Iproteos wins the Expoquimia R+D+I Award in the Biotechnology category

Catalan biotech has won the Expoquimia R+D+I Award in the Biotechnology category for the development of IPR19, a new drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.

The spin-off, founded by two IRB Barcelona scientists leaders in the field of therapeutic peptides, Teresa Tarrago and Ernest Giralt, expect to begin clinical trials of the compound in 2016.

Endowed with € 5,000 in each of their two categories -Biotechnology and Chemistry- the Expoquimia R+D+I Awards were delivered yesterday during the World Chemical Summit Night as part of the Expoquimia Exhibit at the Fair of Barcelona grounds.